Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner

Cancer Research

Volumn 67, Issue 4, 2007, Pages 1555-1562

  Zhang, Chunfu ^a   Jugold, Manfred ^a   Woenne, Eva C ^a   Lammers, Twan ^a   Morgenstern, Bernd ^a   Mueller, Margareta M ^a   Zentgraf, Hanswalter ^a   Bock, Michael ^a   Eisenhut, Michael ^a   Semmler, Wolfhard ^a   Kiessling, Fabian ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER MODEL; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMAGING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MASS SPECTROMETRY; MOLECULAR IMAGING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; UMBILICAL VEIN;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELLS, CULTURED; ENDOTHELIAL CELLS; FERRIC COMPOUNDS; HUMANS; INTEGRIN ALPHAVBETA3; MAGNETIC RESONANCE IMAGING; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; PARTICLE SIZE; PROPYLAMINES; SILANES;

EID: 33847693865     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1668     Document Type: Article

References (45)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
3. Horak ER, Leek R, Klenk N, et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992;340:1120-4.
4. Meitar D, Crawford SE, Rademaker AW, Conn SL. Tumor angiogenesis correlates with metastatic disease, N-myc amplification and poor outcome in human neuroblastoma. J Clin Oncol 1996;14:405-14.
5. Vosseler S, Mirancea N, Bohlen P, Mueller MM, Fusenig NE. Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res 2005;65:1294-305.
6. 5 in ocular neovascular diseases. Proc Natl Acad Sci U S A 1996;93:9764-9.
7. 3 for angiogenesis. Science 1994;264:264:569-71.
8. 3 in small blood vessels of glioblastoma tumors. J Neuropathol Exp Neurol 1996;55:1143-9.
9. Apisarnthanarax S, Chao KS. Current imaging paradigms in radiation oncology. Radiat Res 2005;163:1-25.
10. Mikecz K. Vitarin applied molecular evolution. Curr Opin Investig Drugs 2000;1:199-203.
11. Lainer DT, Brahn E. New antiangiogenic strategies for the treatment of proliferative synovitis. Expert Opin Investig Drugs 2005;14:1-17.
12. Humphries MJ. The LDV peptide motif: its role in integrin-ligand binding. Top Mol Med 1995;1:27-35.
13. Hirano Y, Kando Y, Hayashi T, Goto K, Nakajima A. Synthesis and cell attachment activity of bioactive oligopeptides: RGD, RGDS, RGDV and RGDT. J Biomed Mater Res 1991;25:1523-34.
14. 3 integrin antagonists. J Med Chem 1999;42:3033-40.
15. 18F]Galacto-RGD. PLoS Med 2005;2:244-52.
16. 3-integrin expression. J Nucl Med 2004;45:1776-83.
17. 64Cu-labeled RGD peptide. Bioconjug Chem 2004;15:41-9.
18. 3 integrin binding peptides in a nude mouse model. Cancer Res 2002;62:6146-51.
19. 3 integrin in vivo. Circulation 2004;110:84-90.
20. 3 in brain tumor xenografts. Cancer Res 2004;64:8009-14.
21. Achilefu S, Bloch S, Markiewicz MA, et al. Synergistic effects of light-emitting probes and peptides for targeting and monitoring integrin expression. Proc Natl Acad Sci U S A 2005;102:7976-81.
22. v-integrins. Circulation 2003;107:455-60.
23. 3-expressing cells. Mol Imaging 2004;3:125-34.
24. 3-targeted magnetic resonance imaging. Nat Med 1998;4:623-6.
25. 3-targeted nanoparticle and 1.5 Tesla magnetic resonance imaging. Cancer Res 2003;63:5838-43.
26. 3-targeted paramagnetic nanoparticles. Magn Reson Med 2005;53:621-7.
27. Mulder WJ, Strijkers GJ, Habets JW, et al. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J 2005;19:2008-10.
28. Taupitz M, Schnorr J, Abramjuk C, et al. New generation of monomer-stabilized very small superparamagnetic iron oxide particles (VSOPs) as contrast medium for MR angiography: preclinical results in rats and rabbits. J Mag Reson Imaging 2000;12:905-11.
29. Bach-Gansmo MT. Ferrimagnetic susceptibility contrast agent. Acta Radiol Suppl 1993;387:1-30.
30. Hahn PF, Stark DD, Lewis JM, et al. First clinical trial of a new superparamagnetic iron oxide for use as an oral gastrointestinal contrast agent in MR imaging. Radiology 1990;175:695-700.
31. Saeed M, Wendland MF, Engelbrecht M, Sakuma H, Higgins CB. Value of blood pool contrast agents in magnetic resonance angiography of the pelvis and lower extremities. Eur Radiol 1998;8:1047-53.
32. Bruce IJ, Sen T. Surface modification of magnetic nanoparticles with alkoxysilanes and their application in magnetic bioseparations. Langmuir 2005;21:7029-35.
33. Kohler N, Fryxell GE, Zhang M. A bifunctional poly(ethylene glycol) silane immobilized on metallic oxide-based nanoparticles for conjugation with cell targeting agents. J Am Chem Soc 2004;126:7206-11.
34. Coradin T, Lopez PJ. Biogenic silica patterning: simple chemistry or subtle biology? Chembiochem 2003;4:251-9.
35. Xu Z, Liu Q, Finch JA. Silanation and stability of 3-aminopropyl trimethoxy silane on nanoized superparamagnetic particles. I. Direct silanation. Appl Surf Sci 1997;120:269-78.
36. Massart R. Preparation of aqueous magnetic liquids in alkaline and acidic media. IEEE Trans Magn 1981;17:1247-9.
37. Kiessling F, Fink C, Hansen M, et al. Magnetic resonance imaging of nude mice with heterotransplanted high-grade squamous cell carcinomas (SCC): use of a low loaded, covalently bound Gd-HSA conjugate as contrast agent with high tumor affinity. Invest Radiol 2002;37:193-8.
38. Fusenig NE, Boukamp P. Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes. Mol Carcinog 1998;23:144-58.
39. Mueller M, Peter W, Mappes M, et al. Tumor progression of skin carcinoma cells in vivo promoted by clonal selection, mutagenesis, and autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Am J Pathol 2001;159:1567-79.
40. 1- weighted monitoring of vascularization in human carcinoma heterotransplants by magnetic resonance imaging. Int J Cancer 2003;104:113-20.
41. Gold LI, Jussila T, Fusenig NE, Stenback F. TGF-β isoforms are differentially expressed in increasing malignant grades of HaCaT keratinocytes, suggesting separate roles in skin carcinogenesis. J Pathol 2000;190:579-88.
42. Sun EY, Josephson L, Kelly KA, Weissleder R. Development of nanoparticle libraries for biosensing. Bioconjug Chem 2006;17:109-13.
43. Bogdanowich-Knipp SJ, Chakrabarti S, Williams TD, Dillman RK, Siahaan TJ. Solution stability of linear vs. cyclic RGD peptides. J Pept Res 1999;53:530-41.
44. Raynal I, Prigent P, Peyramaure S, Najid A, Rebuzzi C, Corot C. Macrophage endocytosis of superparamagnetic iron oxide particles: mechanisms and comparison of Ferumoxides and Ferumoxtran-10. Invest Radiol 2004;39:56-63.
45. Lee H, Lee E, Kim DK, Jang NK, Jeong YY, Jon S. Antibiofouling polymer-coated superparamagnetic iron oxide nanoparticles as potential magnetic resonance contrast agents for in vivo cancer imaging. J Am Chem Soc 2006;128:7383-9.